Talimogene Laherparepvec

證據等級: L5

預測適應症: 7 個

Talimogene Laherparepvec: From Unresectable Cutaneous Melanoma to CMM7 (Cutaneous Malignant Melanoma Locus)

One-Sentence Summary

Talimogene laherparepvec (T-VEC) is a GM-CSF-armed, ICP34.5/ICP47-deleted HSV-1 oncolytic virus originally developed for unresectable cutaneous, subcutaneous and nodal melanoma lesions. The TxGNN model's top prediction, CMM7 (a cutaneous malignant melanoma susceptibility locus), scores 99.20% but is currently backed by 0 clinical trials and 0 publications in this evidence pack. Because "CMM7" essentially names the same disease class the drug is already known to be approved for elsewhere, this candidate reads more as a data-gap artifact than a genuine new indication — the registry shows the drug as "not marketed" and lists no original indication, which conflicts with T-VEC's known real-world approval (Imlygic) and should be reconciled before any decision is finalized.

Quick Overview

Item	Content
Original Indication	Not available in this registry (market status shows "not marketed," no license text) — known global approved use is unresectable cutaneous/subcutaneous/nodal melanoma; this is a data gap needing reconciliation
Predicted New Indication	CMM7 (Cutaneous Malignant Melanoma, locus nomenclature)
TxGNN Prediction Score	99.20%
Evidence Level	L4 (mechanism-based reasoning only; no supporting trials or literature)
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not populated in this record, but the repurposing rationale supplied with the prediction describes it: T-VEC is a GM-CSF-modified HSV-1 oncolytic virus (ICP34.5/ICP47-deleted) that, upon intratumoral injection, selectively lyses tumor cells and triggers a systemic anti-tumor immune response.

CMM ("Cutaneous Malignant Melanoma") is a gene-locus naming convention for melanoma susceptibility, and it overlaps almost completely with T-VEC's known approved indication — unresectable cutaneous, subcutaneous, and lymph-node melanoma lesions. In other words, the model is not proposing a mechanistically novel indication so much as re-identifying the drug's existing disease class under a different name.

The evidence pack itself flags this: original_indications is empty and market status is "not marketed," which contradicts the well-established approval of Imlygic (T-VEC) for melanoma. This is judged to be a data-completeness gap in the source registry rather than a mechanistic failure — the underlying biology strongly supports the link, but the administrative record needs correction before this can be treated as an actionable "new" indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Cytotoxicity

(Included because T-VEC targets melanoma and is administered as an oncolytic viral immunotherapy for cancer.)

Item	Content
Cytotoxicity Classification	Immunotherapy (oncolytic virus therapy) — not a conventional cytotoxic chemotherapeutic
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions (live, replication-competent virus — biosafety handling precautions for injection preparation and disposal are typically required for this drug class)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (CMM7) has zero supporting clinical trials or literature and the drug's own regulatory record (original indication, MOA, TFDA labeling) is incomplete — including a blocking gap on package-insert warnings/contraindications needed for any safety review. The lower-ranked candidates (pediatric leptomeningeal melanoma, uveal melanoma, and several non-melanoma carcinomas) score similarly high but were already assessed as Hold due to blood-brain-barrier, tissue-accessibility, or histology mismatches — reinforcing that TxGNN's score here is driven by lexical/knowledge-graph similarity to "melanoma" rather than validated new biology.

To proceed, the following is needed:

Resolve the original-indication/market-status discrepancy by pulling the actual Imlygic (T-VEC) approval record (Fimea/EMA) to correct original_indications and market_status
Obtain the TFDA/EMA package insert for key warnings, contraindications, and DDI data (currently blocking safety review)
Retrieve confirmed mechanism-of-action documentation from DrugBank or the manufacturer label
If CMM7 is intended as a genuinely distinct target population, define it precisely and search for dedicated trials/literature under that specific term rather than relying on melanoma-adjacent scoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.